



June 29, 2026

Notice Regarding Cytokinetics' 340B Contract Pharmacy Policy

Dear Covered Entity,

I am writing to inform you that Cytokinetics is implementing a 340B Contract Pharmacy Policy regarding contract pharmacies' eligibility to receive MYQORZO™ purchased at the 340B discounted price.

Effective August 3, 2026, under this Policy, Cytokinetics will provide 340B pricing for all eligible purchases of MYQORZO™ directly to a 340B covered entity's in-house pharmacy, as listed in the HRSA OPAIS database. Cytokinetics will not facilitate "Bill To/Ship To" orders of any products purchased at the 340B discounted price to contract pharmacies, subject to the following exceptions:

- For 340B covered entities that do not have an in-house pharmacy capable of dispensing MYQORZO™ and that are not already part of the MYQORZO™ Limited Distribution Network, Cytokinetics will permit these covered entities to designate a single contract pharmacy that is part of Cytokinetics' Limited Distribution Network. Only one 340B purchase may occur on a single eligible MYQORZO™ prescription. Multiple requests for 340B dispenses on a single prescription are not permitted.
- Cytokinetics, at its sole discretion, is exempting federal grantees from its 340B Contract Pharmacy Policy. At this time, these covered entities may continue to access products at the 340B price through an unlimited number of contract pharmacies.¹

Cytokinetics will also require the submission of claims data on 340B utilization filled at contract pharmacies for hospital covered entities. All specified claims data must be submitted on the 340B ESP™ platform within 45 days of the date of dispense.

To ensure transparency and program integrity at designated contract pharmacies, Cytokinetics expects that all dispensing to 340B-eligible patients will occur at the properly designated contract pharmacy location, and that 340B drugs will be shipped directly to that location by an authorized distributor.

Cytokinetics is utilizing the 340B ESP™ platform to support contract pharmacy designations and 340B claims data submission. 340B covered entities that haven't already registered an account with 340B ESP™ can make their designations by visiting www.340besp.com/designations. Users that have registered an account with 340B ESP™ can attest to not having an in-house pharmacy and can designate the contract pharmacy by navigating to the Entity Profile tab. Covered entities must make contract pharmacy designations at least 15 calendar days in advance of the date of their first purchase under this practice. If you have questions regarding our 340B distribution model, please contact us at Trade-and-Distribution-DL@cytokinetics.com.

In support of a smooth implementation of our distribution model, 340B covered entities should work with their contract pharmacy administrators and wholesalers to process any outstanding Bill To / Ship To replenishment orders before the effective date of the Policy.

¹ Such federal grantees include Federally Qualified Health Centers (FQHCs), Community Health Centers, Ryan White HIV/AIDS Program Grantees, Title X Family Planning Grantees, Sexually Transmitted Disease (STD) Clinics, Tuberculosis Clinics, Black Lung Clinics, Hemophilia Treatment Centers, Native Hawaiian Health Centers, and Urban Indian Organizations. See 42 U.S.C. § 256b.

FREQUENTLY ASKED QUESTIONS:

Q: Which products are subject to Cytokinetics' policy?

A: Cytokinetics' contract pharmacy policy applies to MYQORZO. Cytokinetics will notify covered entities when additional products are added.

Q: My covered entity has a contract pharmacy relationship with a pharmacy that is owned by our health system. Is this pharmacy subject to Cytokinetics' policy?

A: If your covered entity does not have an in-house pharmacy capable of dispensing Cytokinetics products, your covered entity may elect to designate a contract pharmacy location registered on the HRSA OPAIS database, regardless of ownership interest, as its single contract pharmacy location, provided the designated contract pharmacy is part of Cytokinetics' Limited Distribution Network.

Q: My covered entity has an in-house pharmacy that is capable of purchasing and dispensing Cytokinetics' drugs, but my entity doesn't use it to dispense Cytokinetics' drugs. Can my entity designate one contract pharmacy instead?

A: No, under Cytokinetics' Policy, only a covered entity that does not have its own in-house pharmacy may elect to designate a single contract pharmacy location registered on the HRSA OPAIS database.

Q. My 340B covered entity has contract pharmacy arrangements with multiple locations of the same pharmacy (e.g. six different CareMed pharmacy locations). Can my entity designate all locations of the same pharmacy?

A. No. Cytokinetics' policy allows qualifying 340B covered entities (i.e., covered entities without an in-house pharmacy) to designate a single contract pharmacy location. Contract pharmacy locations are registered individually on the HRSA database and 340B covered entities are permitted to designate only a single contract pharmacy location which corresponds to a single contract pharmacy registration with HRSA.

Q. How often can my covered entity change its contract pharmacy designation?

A. Covered entities may change their contract pharmacy designation once every twelve (12) months (from the date of first designation) or more often if the designated contract pharmacy relationship is terminated from the HRSA OPAIS database.

Q. How does my covered entity change its contract pharmacy designation?

A. Changes to the single contract pharmacy can only be made by visiting www.340Besp.com/designations. Users that have registered an account with 340B ESP™ can navigate to the Entity Profile tab to make their contract pharmacy designation.

Q. How does my covered entity ensure that its eligible contract pharmacy location takes effect on August 3, 2026?

A. For a covered entity's eligible contract pharmacy location to take effect on August 3, 2026, the entity must designate its contract pharmacy by July 24, 2026. After July 24, 2026, please allow 10 business days for the eligible contract pharmacy location to take effect.

Q. How long does it take for my covered entity's eligible contract pharmacy location to take effect after August 3, 2026?

A. Covered entities can take action to comply with Cytokinetics' policy after it goes into effect on August 3, 2026. After August 3, 2026, please allow 10 business days for the eligible contract pharmacy locations to take effect.



Q: How do I submit 340B claims data originating from my single contract pharmacy location designation?

A: 340B covered entities can submit claims under Cytokinetics' policy by registering an account at www.340Besp.com. Users that have registered an account with 340B ESP™ can begin submitting 340B claims for Cytokinetics by navigating to the Claims Data Submission tab. 340B claims must be submitted within 45 days of the date of dispense for the contract pharmacy to remain eligible to receive 340B purchased drugs.

Q: What happens if my organization does not provide 340B claims by the required date?

A: Failure to provide claims data under Cytokinetics' policy may result in the covered entity losing eligibility to purchase products at the 340B price. If you encounter challenges in submitting conforming claims data, please reach out to 340B ESP™ with any questions. Specified claims data must be submitted within 45 days of the date of dispense.